Sanofi Cuts 3-Year Diabetes Sales Forecast as Lantus Slides
- Lantus Slides in U.S. on Slowdown in Basal Insulin Market
- CEO Brandicourt to Present 5-Yr Strategic Plan Next Week
This article is for subscribers only.
Sanofi, France’s biggest company by market value, cut its sales forecast for diabetes therapies in the next three years after demand for its best-selling Lantus insulin slumped.
Diabetes sales will probably drop between 4 percent and 8 percent through 2018 at an average annualized rate and at constant exchange rates, the Paris-based company said in a statement Thursday. Last November, it had forecast slight growth at best. Sanofi shares fell as much as 5.3 percent, the biggest drop in more than two months.